Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of futibatinib in patients benefiting from a prior futibatinib study
2024-512217-40-00Phase 3Authorised
- Sponsor
- Taiho Oncology
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 3, open-label trial of futibatinib in Non-hematologic malignancy (2 arms), sponsored by Taiho Oncology. Primary endpoint: Safety and tolerability. Planned start Oct 2024; status: authorised.
02
Drugs
futibatinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2024-512217-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512217-40-00.